Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule

Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical benefit across cancer indications compared to single agents, albeit with increased toxicity. Leveraging the observation that PD-1 and CTLA-4 are co-expressed by tumor-infiltrating lymphocytes, an inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Berezhnoy, Alexey, Sumrow, Bradley J., Stahl, Kurt, Shah, Kalpana, Liu, Daorong, Li, Jonathan, Hao, Su-Shin, De Costa, Anushka, Kaul, Sanjeev, Bendell, Johanna, Cote, Gregory M., Luke, Jason J., Sanborn, Rachel E., Sharma, Manish R., Chen, Francine, Li, Hua, Diedrich, Gundo, Bonvini, Ezio, Moore, Paul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762776/
https://www.ncbi.nlm.nih.gov/pubmed/33377134
http://dx.doi.org/10.1016/j.xcrm.2020.100163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762776/
https://www.ncbi.nlm.nih.gov/pubmed/33377134
http://dx.doi.org/10.1016/j.xcrm.2020.100163

Ejemplares similares